As­traZeneca says that treme flubbed an­oth­er com­bo can­cer study, rais­ing fresh doubts about a se­r­i­al los­er

As­traZeneca’s bad­ly dam­aged CT­LA-4 strat­e­gy on the im­muno-on­col­o­gy front has tak­en an­oth­er hit.

The phar­ma gi­ant put out word that the sec­ond leg of its CASPI­AN study failed to demon­strate a sig­nif­i­cant­ly im­proved rate of over­all sur­vival among pa­tients giv­en a triplet of Imfinzi, stan­dard of care and the CT­LA-4 treme­li­mum­ab among front­line small cell lung can­cer pa­tients with ex­ten­sive dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER